07:00 , Apr 5, 2010 |  BioCentury  |  Finance

2Q Financial Markets Preview: Wanted Dry Powder

Biotech run-ups have historically cooled after 25-30% gains. Thus the question going into the second quarter is whether there's momentum to keep going, or whether the sector will take a breather. The historical numbers are...
07:00 , Jun 29, 2009 |  BC Week In Review  |  Clinical News

BST-CarGel: Pivotal trial interim data

Interim data from an ongoing, Canadian and European pivotal trial in 22 evaluable patients showed that BST-CarGel treatment of microfractures significantly improved overall International Cartilage Repair Society II scores compared with untreated microfractures (64.5 vs....
08:00 , Feb 9, 2009 |  BC Week In Review  |  Clinical News

BST-CarGel: Completed pivotal trial enrollment

BioSyntech completed enrollment of 80 patients with acute or chronic focal cartilage lesions of the knee in a Canadian and European pivotal trial evaluating microfacture with and without BST-CarGel. BioSyntech Inc. (TSX:BSY), Laval, Quebec  ...
07:00 , Aug 14, 2006 |  BC Week In Review  |  Company News

BioSyntech management update

BioSyntech Inc. (TSX-V:BSY), Laval, Quebec   Business: Musculoskeletal, Dermatology   Hired: Francois Michaud as CFO, formerly CFO of Hemera Technologies Inc.; and Richard Lacombe as VP of clinical affairs, formerly an industry consultant  ...
08:00 , Mar 6, 2006 |  BC Week In Review  |  Clinical News

BST-CarGel: Phase III started

BSY started a Canadian Phase III trial in up to 80 patients. BioSyntech Inc. (TSX-V:BSY), Laval, Quebec   Product: BST-CarGel   Business: Musculoskeletal   Molecular target: Not applicable   Description: BST-Gel hydrogel mixed with the...
08:00 , Feb 20, 2006 |  BC Week In Review  |  Company News

BioSyntech, Kuhnil Pharma Co. Ltd. deal

BSY granted Kuhnil exclusive Korean marketing and distribution rights to BST-CarGel to repair localized cartilage regions and BST-InPod to treat chronic heal pain. Kuhnil purchased 1.5 million BSY shares at C$0.80. BST-CarGel is in Phase...
08:00 , Jan 16, 2006 |  BC Week In Review  |  Clinical News

BioSyntech preclinical data

BSY published in The Journal of Bone and Joint Surgery that, in sheep with damaged cartilage in the knees, BST-CarGel led to significantly more hyaline repair tissue compared with untreated controls at 6 months (p<0.05)....
07:00 , Jul 18, 2005 |  BC Week In Review  |  Company News

BioSyntech, Nicholas Piramal India Ltd. deal

The companies signed a letter of intent for BSY to grant Nicholas Piramal exclusive rights to market and distribute biodegradable thermogel products for wound healing in India, Pakistan, Sri Lanka, Bangladesh, Laos, Cambodia, Vietnam and...
08:00 , Dec 9, 2002 |  BC Week In Review  |  Clinical News

BioSyntech preclinical data

BSYI said that in a C-6 glioma glioblastoma tumor model in Wistar rats, animal receiving Cerebragel stereotactically injected into the tumor site survived beyond 5 months compared to a maximum of 25 days for control...
08:00 , Dec 9, 2002 |  BC Week In Review  |  Company News

BioSyntech, Bioxel, Cook Inc. deal

BIP will supply cGMP paclitaxel under a 5-year agreement with Cook for use in the V-Flex Plus PTX coronary stent system, which is approved in Europe. Separately, BIP completed the sale of cGMP paclitaxel to...